NovoCure Files 8-K with Corporate Updates

TL;DR

NovoCure filed an 8-K on 12/2/24 detailing corporate info, including address in Jersey.

AI Summary

NovoCure Limited filed an 8-K on December 2, 2024, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, with a principal business phone number of +44 (0) 15 3475 6700. The company was formerly known as Novocure Ltd, with a name change effective June 15, 2015.

Why It Matters

This 8-K filing provides essential corporate information and disclosures for NovoCure Limited, including its registered address and contact details, which are important for investors and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases or decreases risk.

Key Players & Entities

• NovoCure Limited (company) — Registrant
• Novocure Ltd (company) — Former company name
• No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (company) — Principal Executive Offices Address
• + 44 (0) 15 3475 6700 (company) — Principal business phone number
• 20150615 (date) — Date of name change
• December 2, 2024 (date) — Date of Report

FAQ

Filing Documents

• nvcr-20241202.htm (8-K) — 26KB
• specialreportdec2024pr.htm (EX-99.1) — 18KB
• 0001645113-24-000034.txt ( ) — 171KB
• nvcr-20241202.xsd (EX-101.SCH) — 2KB
• nvcr-20241202_lab.xml (EX-101.LAB) — 21KB
• nvcr-20241202_pre.xml (EX-101.PRE) — 12KB
• nvcr-20241202_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 2, 2024, the NovoCure Limited ("Novocure") issued a press release announcingthat the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; P =0.039) (N=571). The survival rate benefit for patients treated with TTFields therapy increased over time with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months. TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 and plans to submit the PANOVA-3 results for presentation at an upcoming medical congress. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated December 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: December 2, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR